… erlotinib was compared with chemotherapy (n = 3) or BSC (n = 1). One trial compared the use
of gefitinib with the use of erlotinib… Randomized phase II study of gefitinib versus erlotinib in …

… as first-line therapy for advanced NSCLC, gefitinib was associated with a … gefitinib. We do
not believe that there is a need to a head-to-head clinical trial between gefinitib and erlotinib; …

… Our study suggests that SRC inhibitors merit no further study in patients with EGFR-driven
lung adenocarcinoma. Therefore, these patients remain ideal candidates for clinical trials …

… , but patients with exon 20 point mutations from another phase I study (NCT02113813)
without available standard-of-care therapies could continue ASP8273 under revised consent …

… treatment outcome study (EUTOS) of chronic myelogenous leukemia initiated by Novartis. The
aim of this study … least, be checked in the case of treatment failure or suboptimal response. …

… on continuous treatment with gefitinib or erlotinib within the last 30 days; and no intervening
systemic therapy between cessation of gefitinib or erlotinib and initiation of new therapy (12). …

… -line therapy is still a controversial issue. The aim of this study was to compare the effectiveness
of gefitinib, erlotinib, and … NSCLC including 147 patients treated with EGFR TKIs. Time to …

… In the present study, the disease control rate for erlotinib treatment … In our study, the response
rate to erlotinib treatment after gefitinib failure was lower than that to the gefitinib treatment …

… study, the primary objective was to determine the pooled overall treatment effect on OS of
firstline therapy with gefitinib … this meta-analysis of gefitinib and erlotinib as most of the included …

… Erlotinib induced gastrointestinal bleeding is rare, and dose-related. We are reporting a lung
cancer patient who received erlotinib and gefitinib. … used in this study were lower than those …